AI assistant
Dr. Lal Pathlabs Limited — Earnings Release 2023
May 11, 2023
61783_rns_2023-05-11_0490c6ec-4cd2-4b67-a18d-06c87a181b3e.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [598 x 65] intentionally omitted <==
May 11, 2023
National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001
Symbol: LALPATHLAB Scrip Code: 539524
Sub: Press Release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023
Dear Sir/ Madam,
Please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023.
We request you to please take the same on record.
Thanking You, Yours Faithfully,
For Dr. Lal PathLabs Limited
Ved Prakash Goel Digitally signed by Ved Prakash Goel DN: c=IN, st=Haryana, 2.5.4.20=bcdd06c1b82c1c0fff85025f4c956bdba0aa042faaab4c6a9528a2543ae5229d, postalCode=122101, street=SECTOR 65 , M3M GOLF ESTATE , Badshahpur , Gurgaon, pseudonym=d41d8cd98f00b204e9800998ecf8427e, serialNumber=be171ab0ad537f5f0e661812e5f977f9f883bbf9bfe858889f67f002afdf2650, o=Personal, cn=Ved Prakash Goel Date: 2023.05.11 14:19:43 +05'30'
Ved Prakash Goel Group Chief Financial Officer
Encl.: As above
==> picture [588 x 67] intentionally omitted <==
May 11, 2023
For Immediate Release
==> picture [159 x 37] intentionally omitted <==
Dr Lal PathLabs Limited records revenue of Rs 491 Cr in Q4 FY 2022-23
New Delhi, India, May 11, 2023 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2023.
Consolidated Performance Highlights: Q4 FY 2022-23 vs Q4 FY 2021-22
-
Non-Covid Revenue increased by 14.4% in Q4 FY23 & 15.5% in FY23
-
Normalised EBITDA margin (after adjustment for stock based compensation, CSR & exceptional expenses) for Q4 FY23 is 26.6% & 26.2% for FY23
-
Normalised PAT* margin for Q4 FY23 is 15.5% and 14.7% for FY23
Financial Overview (Consolidated) in Rs Cr
==> picture [364 x 277] intentionally omitted <==
----- Start of picture text ----- Q4 FYParticularsFY23 FY22 Gr % FY23 FY22 Gr %Revenue 491 486 1.1% 2017 2087 -3.4%Non Covid 480 420 14.4% 1954 1691 15.5%Covid & Allied 11 66 -83.4% 63 396 -84.1%Operating Expenditure 360 355 1.5% 1489 1487 0.1%Normalised EBITDA 131 131 0.0% 528 600 -12.1%Margins 26.6% 26.9% 26.2% 28.8%RSU & CSR cost 8 10 31 40Exceptional Item 7 0 7 0EBITDA 116 121 -4.4% 490 561 -12.6%Margins 23.6% 24.9% 24.3% 26.9%Other Income 14 12 42 53Depreciation Cost 38 38 150 108EBIT 92 95 -3.2% 381 505 -24.5%Finance Cost 9 12 38 30PBT 83 84 -0.3% 344 475 -27.6%Margins 17.0% 17.2% 17.0% 22.8%PAT 57 62 -8.2% 241 350 -31.2%Margins 11.6% 12.8% 12.0% 16.8%EPS 6.8 7.4 -7.8% 28.8 41.7 -30.9%Normalised PBT* 102 94 8.2% 400 494 -19.0%Margins 20.8% 19.4% 19.8% 23.7%Normalised PAT* 76 73 4.1% 297 369 -19.5%Margins 15.5% 15.0% 14.7% 17.7%Normalised EPS* 9.1 8.7 4.5% 35.5 44.0 -19.2%----- End of picture text -----
- *Normalised PBT and PAT are excluding notional depreciation of Rs. 12 Cr. in Q4 FY23, Rs. 49 Cr. in FY23 and Rs. 11 Cr. in Q4 FY22, Rs. 19 Cr. in FY22 and exceptional expenses of Rs. 7 Cr.in Q4 and FY’23.
Classification: Internal
Dr Lal Pathlabs Limited
1
12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com
==> picture [159 x 37] intentionally omitted <==
About Dr Lal PathLabs Limited
Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
As on March 31, 2023 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers.
Contact Details
Ved Goel Group Chief Financial Officer Dr Lal PathLabs Limited
+91 124 3016500 [email protected]
Rakshit Tewari/ Kritika Khatwani Adfactors PR
+91 9935551036/+91 8604801332 [email protected] [email protected]
For further information on Dr Lal PathLabs see www.lalpathlabs.com
Safe Harbour
This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.
Classification: Internal
Dr Lal Pathlabs Limited
12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com
2